{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:39:30Z","timestamp":1765888770343,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s13555-021-00659-w","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T07:02:35Z","timestamp":1640329355000},"page":"451-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-6844","authenticated-orcid":false,"given":"Masayuki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujio","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"issue":"3","key":"659_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201\u201322.","journal-title":"J Dermatol"},{"issue":"5","key":"659_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"659_CR3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/1346-8138.13859","volume":"44","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Satoh K, Takagi A, Iizuka H. Economic burden of psoriatic patients in Japan: analysis from a single outpatient clinic. J Dermatol. 2017;44(9):1024\u20136.","journal-title":"J Dermatol"},{"issue":"1","key":"659_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"659_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"8","key":"659_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/1346-8138.13829","volume":"44","author":"M Ohtsuki","year":"2017","unstructured":"Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44(8):873\u201384.","journal-title":"J Dermatol"},{"issue":"11","key":"659_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/1346-8138.14617","volume":"45","author":"M Kishimoto","year":"2018","unstructured":"Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45(11):1345\u20138.","journal-title":"J Dermatol"},{"issue":"4","key":"659_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/09546634.2018.1525480","volume":"30","author":"C Ohata","year":"2019","unstructured":"Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis. J Dermatol Treat. 2019;30(4):383\u20136.","journal-title":"J Dermatol Treat"},{"issue":"12","key":"659_CR9","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/1346-8138.15104","volume":"46","author":"H Saruwatari","year":"2019","unstructured":"Saruwatari H. Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. J Dermatol. 2019;46(12):1166\u20139.","journal-title":"J Dermatol"},{"issue":"7","key":"659_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1346-8138.14943","volume":"46","author":"M Kishimoto","year":"2019","unstructured":"Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46(7):615\u20137.","journal-title":"J Dermatol"},{"key":"659_CR11","unstructured":"Japanese Society for Pharmacoepidemiology, Drug Epidemiology and Database Task Force Activities. Survey of Japanese databases in Japan available for clinical\/pharmaco-epidemiology. September 2019. http:\/\/www.jspe.jp\/committee\/020\/0210\/. Accessed 19 Jan 2021."},{"issue":"6","key":"659_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/1346-8138.14870","volume":"46","author":"Y Tada","year":"2019","unstructured":"Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466\u201377.","journal-title":"J Dermatol"},{"issue":"1","key":"659_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/cer-2018-0097","volume":"8","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, et al. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019;8(1):45\u201354.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"659_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13696998.2019.1571500","volume":"22","author":"JJ Wu","year":"2019","unstructured":"Wu JJ, Pelletier C, Ung B, Tian M. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. J Med Econ. 2019;22(4):365\u201371.","journal-title":"J Med Econ"},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09546634.2019.1698699","volume":"32","author":"SR Feldman","year":"2021","unstructured":"Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, et al. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatol Treat. 2021;32:203\u201311.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"659_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/09546634.2017.1341607","volume":"29","author":"S Imafuku","year":"2018","unstructured":"Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. J Dermatol Treat. 2018;29(1):24\u201331.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"659_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12895-018-0074-0","volume":"18","author":"R Sruamsiri","year":"2018","unstructured":"Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5.","journal-title":"BMC Dermatol"},{"issue":"4","key":"659_CR18","first-page":"336","volume":"18","author":"M Aljaser","year":"2019","unstructured":"Aljaser M, Amar L, Kircik LH. Use of apremilast in patients who are dissatisfied with stable maintenance topical therapy. J Drugs Dermatol. 2019;18(4):336\u201340.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"659_CR19","first-page":"957","volume":"16","author":"J Bagel","year":"2017","unstructured":"Bagel J, Nelson E, Keegan BR. Apremilast and narrowband ultraviolet-B combination therapy for treating moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2017;16(10):957\u201362.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00659-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T18:20:14Z","timestamp":1646763614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00659-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00659-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ORCiD for Masayuki Tanaka corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}